Sveriges Riksbank
| Bid date, 2021-01-15 | |
| Bid Submission Date | 2021-01-15 |
| Bid times | 10.30-11.00 (CET/CEST) on the Bid date |
| Offered Amount | 50 billion SEK |
| Maximum Permitted Bid Volume | 12.5 billion SEK from an individual bidder |
| Settlement Date | 2021-01-19 |
| Minimum Permitted Bid Volume | 10 million SEK per bid |
| Final Repayment Date | 2025-01-20 |
| Maximum Allocation | 25 per cent of Offered Amount |
| Allocation Time | No later than 11.30 (CET/CEST) on the Bid date |
| Repayment Date | 2022-01-19 |
| Option Repayment Date 1 | 2023-01-19 |
| Option Repayment Date 2 | 2024-01-19 |
| Interest rate | The Riksbank´s applicable repo rate |
| Additional interest rate | 0.10 per cent |
| Confirmation of bids to e-mail | eol@riksbank.se |
Stockholm, 2021-01-13
This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
ALK Abello19.12.2025 22:46:46 CET | Press release
Major shareholder announcement
ALK Abello19.12.2025 22:46:46 CET | Pressemeddelelse
Storaktionærmeddelelse
Zealand Pharma19.12.2025 22:00:00 CET | Press release
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Boehringer Ingelheim Limited19.12.2025 21:10:00 CET | Press release
U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults
Novartis Pharma AG19.12.2025 20:30:06 CET | Press release
Novartis and US government reach agreement on lowering drug prices in the US
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
